Publications

Found 148 results
[ Type(Desc)] Year
Journal Article
AM Kabadi, DG Ousterout, IB Hilton, and CA Gersbach. "Multiplex CRISPR/Cas9-based genome engineering from a single lentiviral vector." Nucleic Acids Research 42, no. 19 (2014).
MA Lan, CA Gersbach, KE Michael, BG Keselowsky, and AJ García. "Myoblast proliferation and differentiation on fibronectin-coated self assembled monolayers presenting different surface chemistries." Biomaterials 26, no. 22 (2005): 4523-4531.
JB Kwon, A Vankara, AR Ettyreddy, JD Bohning, and CA Gersbach. "Myogenic Progenitor Cell Lineage Specification by CRISPR/Cas9-Based Transcriptional Activators." Stem Cell Reports 14, no. 5 (2020): 755-769.
PY Hwang, L Jing, J Chen, F-L Lim, R Tang, H Choi, KM Cheung, MV Risbud, CA Gersbach, F Guilak et al. "N-cadherin is Key to Expression of the Nucleus Pulposus Cell Phenotype under Selective Substrate Culture Conditions." Scientific Reports 6 (2016).
A Pickar-Oliver, and CA Gersbach. "The next generation of CRISPR-Cas technologies and applications." Nature Reviews. Molecular Cell Biology 20, no. 8 (2019): 490-507.
K Saha, EJ Sontheimer, PJ Brooks, MR Dwinell, CA Gersbach, DR Liu, SA Murray, SQ Tsai, RC Wilson, DG Anderson et al. "The NIH Somatic Cell Genome Editing program." Nature 592, no. 7853 (2021): 195-204.
K Bulaklak, and CA Gersbach. "The once and future gene therapy." Nature Communications 11, no. 1 (2020).
LR Polstein, and CA Gersbach. "Photoregulated gene expression in human cells with light-inducible engineered transcription factors." Asme 2012 Summer Bioengineering Conference, Sbc 2012 (2012): 351-352.
AM D'Ippolito, IC McDowell, A Barrera, LK Hong, SM Leichter, LC Bartelt, CM Vockley, WH Majoros, A Safi, L Song et al. "Pre-established Chromatin Interactions Mediate the Genomic Response to Glucocorticoids." Cell Systems 7, no. 2 (2018): 146-160.e7.
A Dicks, C-L Wu, N Steward, SS Adkar, CA Gersbach, and F Guilak. "Prospective isolation of chondroprogenitors from human iPSCs based on cell surface markers identified using a CRISPR-Cas9-generated reporter." Stem Cell Research & Therapy 11, no. 1 (2020).
CA Gersbach, and R Barrangou. "Pulling the genome in opposite directions to dissect gene networks." Genome Biology 19, no. 1 (2018).
DG Ousterout, P Perez-Pinera, PI Thakore, AM Kabadi, MT Brown, X Qin, O Fédrigo, V Mouly, JP Tremblay, and CA Gersbach. "Reading frame correction by targeted genome editing restores dystrophin expression in cells from duchenne muscular dystrophy patients." Molecular Therapy 21, no. 9 (2013): 1718-1726.
M Mao, C-C Chang, A Pickar-Oliver, LD Cervia, L Wang, J Ji, PB Liton, CA Gersbach, and F Yuan. "Redirecting Vesicular Transport to Improve Nonviral Delivery of Molecular Cargo." Advanced Biosystems 4, no. 8 (2020).
CL Frank, F Liu, R Wijayatunge, L Song, MT Biegler, MG Yang, CM Vockley, A Safi, CA Gersbach, GE Crawford et al. "Regulation of chromatin accessibility and Zic binding at enhancers in the developing cerebellum." Nat Neurosci 18, no. 5 (2015): 647-656.
P Perez-Pinera, DD Kocak, CM Vockley, AF Adler, AM Kabadi, LR Polstein, PI Thakore, KA Glass, DG Ousterout, KW Leong et al. "RNA-guided gene activation by CRISPR-Cas9-based transcription factors." Nature Methods 10, no. 10 (2013): 973-976.
PI Thakore, JB Kwon, CE Nelson, DC Rouse, MP Gemberling, ML Oliver, and CA Gersbach. "RNA-guided transcriptional silencing in vivo with S. aureus CRISPR-Cas9 repressors." Nature Communications 9, no. 1 (2018).
JP Beyersdorf, S Bawage, N Iglesias, HE Peck, RA Hobbs, JA Wroe, C Zurla, CA Gersbach, and PJ Santangelo. "Robust, Durable Gene Activation In Vivo via mRNA-Encoded Activators." Acs Nano 16, no. 4 (2022): 5660-5671.
TM Gibson, and CA Gersbach. "The role of single-cell analyses in understanding cell lineage commitment." Biotechnology Journal 8, no. 4 (2013): 397-407.
CA Gersbach, BA Byers, GK Pavlath, and AJ García. "Runx2/Cbfa1 stimulates transdifferentiation of primary skeletal myoblasts into a mineralizing osteoblastic phenotype." Experimental Cell Research 300, no. 2 (2004): 406-417.
CA Gersbach. "Runx2/Cbfa1 stimulates transdifferentiation of primary skeletal myoblasts into a mineralizing osteoblastic phenotype." Exp. Cell Res. 300 (2004): 406-417.
CA Gersbach, BA Byers, GK Pavlath, RE Guldberg, and AJ García. "Runx2/Cbfa1-genetically engineered skeletal myoblasts mineralize collagen scaffolds in vitro." Biotechnology and Bioengineering 88, no. 3 (2004): 369-378.
CA Gersbach, JE Phillips, RE Guldberg, and AJ García. "Runx2-genetically engineered cells for bone tissue engineering." Proceedings of the 2005 Summer Bioengineering Conference 2005 (2005): 603-604.
CA Gersbach, BA Byers, RE Guldberg, GK Pavlath, and AJ García. "Runx2-stimulated transdifferentiation of primary skeletal myoblasts into an osteoblastic mineralizing phenotype for bone tissue engineering." Transactions 7th World Biomaterials Congress (2004).
JM Brunger, NPT Huynh, CM Guenther, P Perez-Pinera, FT Moutos, J Sanchez-Adams, CA Gersbach, and F Guilak. "Scaffold-mediated lentiviral transduction for functional tissue engineering of cartilage." Proceedings of the National Academy of Sciences of the United States of America 111, no. 9 (2014): E798-E806.
TS Klann, GE Crawford, TE Reddy, and CA Gersbach. "Screening Regulatory Element Function with CRISPR/Cas9-based Epigenome Editing." Methods Mol Biol 1767 (2018): 447-480.

Pages